On March 12, 2022, the "Qiannan Tumor Specialist Alliance Salon" hosted by Qiannan Hospital of Traditional Chinese Medicine was grandly held in Qiannan City, Guizhou.

Professor Lu Wei, Department of Pain, Cancer Hospital Affiliated to Guizhou Medical University, Professor Xu Jing, Department of Oncology, Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Dr. Chen Jiang, Chief Physician, Department of Anorectal, First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Li Xuesong, Department of Oncology, Qixingguan District People's Hospital Professors and many other experts gathered together to conduct in-depth discussions and exchanges on the progress of multidisciplinary tumor treatment.

The opening ceremony was delivered by Director Huang Jun of Qiannan Prefecture Hospital of Traditional Chinese Medicine. The content of this conference covers "non-drug treatment of intractable cancer pain", "clinical application of NOTES, Noses, and TUES technology in abdominal surgery", "gynecological tumors and genetics", "comprehensive treatment of malignant tumors", etc. , Through the collision of multidisciplinary tumor treatment ideas, a tumor treatment plan with innovative ideas is obtained. With the development of this meeting, Mengyang Pharmaceutical brought the company's flagship product "Shengbai Oral Liquid (Mixture)" to display at the meeting.

During the meeting, Professor Xu Jing from the Oncology Department of the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine shared the "Clinical Research Progress of Shengbai Oral Liquid" at the meeting. Shengbai oral liquid (mixture), as a treatment drug for leukopenia caused by cancer radiotherapy and chemotherapy, has been included in the 2020 edition of the Chinese Pharmacopoeia. Consensus recommendations for treatment. It has a clear curative effect on the prevention and treatment of myelosuppression after radiotherapy and chemotherapy in cancer patients, and it also has a clear curative effect on improving clinical symptoms such as dizziness, fatigue, chills and limbs, and sore waist and knees. Professor Xu Jing gave a vivid and specific explanation of the mechanism of action of Shengbai Oral Liquid (Mixture) based on the results of modern pharmacological research. Through the report on the results of preclinical research and RCT evaluation after listing, the participating experts deeply understood Product effectiveness and safety. The academic atmosphere at the meeting was strong, with heated discussions and enthusiastic responses.

The meeting gathered multidisciplinary tumor diagnosis and treatment experts, and conducted professional learning and discussions on intractable cancer pain, digestive tumors, gynecological tumors, and adverse reactions of tumor treatment, treatment progress, and guideline interpretation. The successful holding of this meeting will further improve the diagnosis and treatment level of tumor treatment in this region, and will also be a blessing to many cancer patients.